Palatin Technologies, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Palatin Technologies, Inc. Palatin Technologies, Inc. (PTN) is a biopharmaceutical company developing first-in-class medicines that modulate the melanocortin receptor system to treat diseases with significant unmet medical needs, including inflammatory, autoimmune, ocular, and metabolic conditions; its pipeline features receptor-specific agonists such as PL9643 for dry eye disease in Phase 3, PL8177 oral peptide for ulcerative colitis in Phase 2, PL7737 oral MC4R agonist in preclinical studies for obesity, long-acting peptide MC4R agonists, bremelanotide co-administered with tirzepatide for obesity in Phase 2, and bremelanotide co-formulated with PDE5 inhibitors for erectile dysfunction. Founded in 1986 and headquartered in Cranbury, New Jersey, the company operates primarily in the United States with a strategic focus on peptide-based therapeutics targeting melanocortin receptors to resolve harmful inflammation via the body's natural pathways. Recent developments include the completion of a 1-for-50 reverse stock split in August 2025, an upsized $18.2 million public offering closing in November 2025, positive preclinical efficacy data for PL7737 in obesity models announced in July 2025, presentations on melanocortin therapies for obesity at ObesityWeek 2025 in November, a strategic collaboration with Boehringer Ingelheim announced in August 2025 for melanocortin-targeted retinal disease treatments including diabetic retinopathy with an upfront payment and potential milestones up to €278 million plus royalties, and a €5.5 million milestone payment earned from that partnership in September 2025; earlier, in late 2023, it sold Vyleesi commercialization rights to Cosette Pharmaceuticals for up to $171 million to refocus on its melanocortin pipeline.
Company News
What Palatin Technologies (PTN) Said on Its Q4 Earnings Call
Palatin Technologies, Inc. (PTN) Q4 2026 Earnings Call Transcript
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update
StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It
Palatin to Begin Trading on Nasdaq Stock Exchange
Palatin Technologies, Inc. (PTN) Q3 2026 Earnings Call Transcript
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Palatin Technologies Q2 Earnings Call Highlights
Palatin Technologies, Inc. (PTN) Q2 2026 Earnings Call Transcript
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Why Are Palatin Technologies (PTN) Shares Spiking After-Hours?
Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More
Palatin Technologies, Inc. (PTN) Q1 2026 Earnings Call Transcript
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Palatin Technologies Announces Pricing of Upsized $15.8 Million Public Offering
Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim
Boehringer Ingelheim and Palatin Technologies to develop potential first-in-class melanocortin receptor targeted treatment for patients with retinal diseases